Search
Jupiter Neurosciences Inc
JUNSAdd to Watchlist
0.227USD
+0.004+1.88%
Market hours （ET）Quotes delayed by 15 min
8.24MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02No earnings forecast score is currently available for Jupiter Neurosciences Inc. The Biotechnology & Medical Research industry's average is 8.14.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Jupiter Neurosciences Inc
JUNS
1
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Jupiter Neurosciences Inc's expected revenue for the next quarter?
Jupiter Neurosciences Inc's expected revenue is 225.00K.
How have Jupiter Neurosciences IncJUNS's recent earnings per share performed?
The market expectation was USD -0.06, while Jupiter Neurosciences IncJUNS's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.05.
What is the analyst rating for Jupiter Neurosciences Inc?
Based on the ratings of Jupiter Neurosciences Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.